The stock has a 36-month beta value of 0.65. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VRDN is 73.28M, and at present, short sellers hold a 13.86% of that float. On April 11, 2025, the average trading volume of VRDN was 984.03K shares.
VRDN) stock’s latest price update
The stock of Viridian Therapeutics Inc (NASDAQ: VRDN) has decreased by -3.22 when compared to last closing price of 11.79. Despite this, the company has experienced a -9.80% fall in its stock price over the last five trading sessions. businesswire.com reported 2025-04-07 that WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement.
VRDN’s Market Performance
VRDN’s stock has fallen by -9.80% in the past week, with a monthly drop of -31.47% and a quarterly drop of -40.42%. The volatility ratio for the week is 13.14% while the volatility levels for the last 30 days are 6.89% for Viridian Therapeutics Inc The simple moving average for the past 20 days is -17.44% for VRDN’s stock, with a -36.73% simple moving average for the past 200 days.
Analysts’ Opinion of VRDN
Many brokerage firms have already submitted their reports for VRDN stocks, with Wells Fargo repeating the rating for VRDN by listing it as a “Equal Weight.” The predicted price for VRDN in the upcoming period, according to Wells Fargo is $27 based on the research report published on December 19, 2024 of the previous year 2024.
Needham gave a rating of “Buy” to VRDN, setting the target price at $38 in the report published on September 11th of the previous year.
VRDN Trading at -26.98% from the 50-Day Moving Average
After a stumble in the market that brought VRDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.05% of loss for the given period.
Volatility was left at 6.89%, however, over the last 30 days, the volatility rate increased by 13.14%, as shares sank -27.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.28% lower at present.
During the last 5 trading sessions, VRDN fell by -9.80%, which changed the moving average for the period of 200-days by -13.63% in comparison to the 20-day moving average, which settled at $13.82. In addition, Viridian Therapeutics Inc saw -40.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRDN starting from Beetham Thomas W., who purchase 5,000 shares at the price of $23.41 back on Sep 27 ’24. After this action, Beetham Thomas W. now owns 6,000 shares of Viridian Therapeutics Inc, valued at $117,050 using the latest closing price.
Mahoney Stephen F., the President and CEO of Viridian Therapeutics Inc, purchase 21,400 shares at $23.33 during a trade that took place back on Sep 27 ’24, which means that Mahoney Stephen F. is holding 21,400 shares at $499,262 based on the most recent closing price.
Stock Fundamentals for VRDN
Current profitability levels for the company are sitting at:
- -990.19 for the present operating margin
- -19.32 for the gross margin
The net margin for Viridian Therapeutics Inc stands at -893.87. The total capital return value is set at -0.43. Equity return is now at value -45.77, with -41.35 for asset returns.
Based on Viridian Therapeutics Inc (VRDN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -11.01. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -98.17.
Currently, EBITDA for the company is -266.36 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 2818.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.43.
Conclusion
To sum up, Viridian Therapeutics Inc (VRDN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
